ArcaScience utilizes an AI-driven platform to analyze over 100 billion patient data points, enabling pharmaceutical companies and CROs to enhance drug development and safety monitoring. The platform addresses the challenge of optimizing clinical trials and drug lifecycle management by providing actionable insights for benefit-risk assessment and patient-centric decision-making.
Funding
Funding not disclosed
PAFounders
Product
Problem
Pharmaceutical companies and CROs face challenges in optimizing clinical trials and drug lifecycle management due to the difficulty of extracting actionable insights from vast amounts of patient data. Traditional methods struggle to efficiently assess benefit-risk profiles and make patient-centric decisions throughout the drug development process.
Solution
ArcaScience offers an AI-driven platform that analyzes over 100 billion patient data points to enhance drug development and safety monitoring. The platform provides tailored studies and critical insights to de-risk, build, and maintain more efficient treatments. By integrating patient data and artificial intelligence, ArcaScience enables patient centricity and delivers better and safer drugs at scale. The platform's AI models bring original patient-centric information to help clinicians and safety specialists deliver better drugs at scale.
Target Audience
The primary users are pharmaceutical companies, CROs, clinicians, and safety specialists involved in drug development, clinical trials, and post-market safety monitoring.
Features
- **A.S Trial Balancer:** AI-assisted benefit-risk prediction to differentiate promising drugs before clinical trials.
- **A.S Safety Shield:** Safety Monitoring Report for AI-driven insights for informed signal detection.
- **A.S Trial Designer:** AI-assisted endpoint discovery to identify the right clinical endpoints (COAs) for clinical trials.
- **A.S KOL Finder:** AI-assisted KOL identification to improve clinical trial recruitment.
- **A.S Therapeutic Horizon:** A search engine for literature review.
- **A.S Trial Scanner:** Integrates data into eCRFs to handle real-world studies.
- **Endpoint Study:** Identifies promising COAs, PROMs, and ClinROs for a specific pathology.
- **Benefit-Risk Study:** Predicts the benefit-risk profile of drugs at the earliest stages.
- **KOL Study:** Delivers recruitment sites data and analytics linked to a trial's pathology and patient population.